[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639782":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":20,"responsibleParty":39,"collaborators":11,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":11,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":48,"maxAge":11,"enrollmentInfo":49,"targetDuration":11,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":11,"overallStatus":58,"whyStopped":11,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Extra PET\u002FCT scan at 1 to 2 additional, later time-point(s) after injection than current practice","EXPERIMENTAL",null,[13],"Radiation: Late scan time-point(s) optimalisation of 89Zr trastuzumab18F-Fluoroestradiol",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"RADIATION","Late scan time-point(s) optimalisation of 89Zr trastuzumab18F-Fluoroestradiol","Patients who consent in participating will be scanned at one to two additional time-point(s) after injection, at a time-point that is later than the one currently used in practice.",[9],[21],{"facility":5,"status":11,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Groningen","Provincie Groningen","9717GZ","Netherlands","NL",{"type":28,"coordinates":29},"Point",[30,31],6.56667,53.21917,{"lat":31,"lon":30},[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Brouwers","CONTACT","+31 50 361 6161","a.h.brouwers@umcg.nl",{"type":40,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100639782","late-scan-time-point-optimalisation-of-18f-fluoroestradiol-for-the-large-field-of-view-lafov-petct-scanner-100639782",false,"NCT07627269","Late Scan Time-point Optimalisation of 18F-Fluoroestradiol for the Large Field-of-view (LAFOV) PET\u002FCT Scanner.","Inclusion Criteria:\n\n* Patients who are referred for PET\u002FCT imaging with 18F-Fluoroestradiol will be included in this study.\n\nExclusion Criteria:\n\n* Patients who are not able to lay down in supine position for up to one hour.","ALL","16 Years",{"count":50,"type":51},8,"ESTIMATED","INTERVENTIONAL",[54],"NA","Currently, in routine patient care PET\u002FCT scan protocols used on high sensitivity large field of-view (LAFOV) PET\u002FCT systems are based on protocols that historically were developed for standard field-of-view (SAFOV) PET\u002FCT systems with a much lower sensitivity profile. In the current SAFOV-based imaging protocols, the maximum delay between injection and actual scanning is limited by increasing noise (due to radioactive decay) resulting in bad image quality. A major advantage of later time-point imaging in general is, that the target-to background ratio improves. With the high-sensitive LAFOV PET\u002FCT scanner later time-point imaging becomes possible, and higher tumour-to background ratios can be obtained. Specifically for the 18F-Fluoroesradiol tracer, used to image estrogen receptor positive tumors, high physiological uptake in the liver and intestines hampers the visualization and quantification of liver metastases and peritoneal metastases. The aim of this study is to evaluate whether late time point imaging with the 18F-Fluoroestradiol tracer on the LAFOV PET\u002FCT improves visualization and quantification of liver metastases and peritoneal metastases.",[57],"Breast Cancer","NOT_YET_RECRUITING","2026-05-29",{"date":61,"type":62},"2026-06-04","ACTUAL",{"date":64,"type":51},"2026-06-01",{"date":66,"type":51},"2030-08-01",{"name":5,"class":6},1]